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total hip replacement (THR) separately. Efﬁcacy data were
extracted from published randomised controlled trials. Cost data
were derived from the literature and other published sources and
natural history data after VTE from observational studies. Costs
were expressed in 2003 Swiss Francs (CHF) and effects as life-
years gained (LYG). Deterministic sensitivity analysis was used
to assess the robustness of the model. RESULTS: In patients
undergoing HFS, the incremental cost-effectiveness ratio (ICER)
of extended fondaparninux prophylaxis versus a one-week
regimen was CHF 2920/LYG after 30 days, with cost-savings
reached after 5 years. In patients undergoing THR, the ICER of
extended fondaparninux prophylaxis versus a 1-week regimen
was CHF 21183/LYG after 30 days, with cost-savings reached
after 5 years. CCONCLUSIONS: Within the limitations of the
model, extended prophylaxis with fondaparinux is cost-effective
for the prevention VTE in major orthopaedic surgery in 
Switzerland.
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OBJECTIVES: ISAM, a multicenter, observational, retrospec-
tive, cross-sectional study, aimed at describing the anticoagula-
tion treatment monitoring on patients with chronic non-valvular
atrial ﬁbrillation (CNVAF), receiving Oral Anticoagulation
Therapy (OAT) for stroke prophylaxis, (follow-up Jan-Dec
2002); and estimating direct and indirect costs in the Italian
National Health System perspective. METHODS: Seven out of
8 Anti-Coagulation Clinics (ACC’s), selected to represent the
whole Italian territory, enrolled 23 randomized patients with
CNVAF. RESULTS: The total number of patients was 177 :102
males and 75 females (mean age 72 years); 90% with chronic
Atrial Fibrillation and 10% with paroxysmal; 77% subjects
received warfarin and 23% acenocumarol. Forty percent of all
tests required dosage changes and the mean interval between two
consecutive tests was 20 days. The quality of OAT monitoring,
according to Rosendaal’s analysis, was: 67.9% of time spent in
the range 2.0–3.0, 21% below and 10% above this range. Unit
costs, using National tariffs were: 5.16€ and 12.91€ for INR 
tests and visits respectively, retail price for drugs (warfarin:
0.0145€/mg; acenocumarol: 0.0095€/mg) and appropriate DRG
tariffs for admissions. Total cost per patient per year was 943€:
745€ direct costs and 198€ indirect ones. Medical costs, 525€,
included OAT drug (5%), INR tests (18%), monitoring visits
(44%) and admissions (33%); non-medical costs (transporta-
tion) amounted to 220€. CONCLUSIONS: Patients in ACC
management could obtain good level of INR control: Time in
Target Range (TTR) 67.9%. ISAM is a ﬁrst attempt to assess
cost of OAT monitoring in Italy, conﬁrming that AF is a growing
health problem, as well as a cause of health costs that includes
drugs, INR tests and monitoring visits, which are the most deter-
minant in the total costs. In addiction, indirect costs (productiv-
ity loss by patients or their caregivers) were 21% of total costs.
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OBJECTIVES: To evaluate the preferences of physicians and
pharmacists toward products used for replacement therapy.
METHODS: This study investigates preferences on hemophilia
care in 69 physicians and 58 pharmacists using conjoint analy-
sis, a technique for establishing the relative importance of dif-
ferent characteristics in the provision of a good or service.
Attributes and levels were: perceived viral safety (as that pro-
vided by highly puriﬁed double inactivation plasma derived
versus recombinant concentrates), risk of inhibitor development
(1/4, 1/6, 1/10 PUP’s), factor infusion frequency on prophylaxis
(thrice, twice, once a week), pharmaceutical dosage form
(lyophilized material or a ready-to-use solution), way of distrib-
ution (home, ofﬁce pharmacy, hospital) and price. RESULTS:
Excluding pharmaceutical dosage form for physicians and ofﬁce
pharmacy delivery for pharmacists, all attributes considered
tested important to respondents. Physicians showed a strong
preference toward both outcome variables (viral safety, risk of
development of inhibitors) and process variables (distribution,
infusion frequency) while pharmacists showed a strong prefer-
ence only for outcome variables and unexpectedly not toward
way of distribution. CONCLUSIONS: Our study is the ﬁrst to
apply conjoint analysis to establish preferences of physicians and
pharmacists in hemophilia replacement therapy. This study pro-
vided evidence of the usefulness of conjoint analysis in plan
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optimal health care through the elicitation of physicians’ and
pharmacists’ preferences to health care, even in the particular
context of hemophilia management.
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OBJECTIVES: Inadequate treatment of haemophiliacs leads to
high rate of chronic arthropathy, high number of transfusion-
transmitted diseases and poor social integration. The objectives
of our study were to measure HRQOL and utilities in
haemophilia patients and to evaluate the inﬂuence of
haemophilia severity, patient’s age and socio-professional status
on HRQOL and utilities. METHODS: We used SF-36 and EQ-
5D questionnaires in 100 haemophilia patients with severe (66),
moderate (18) and mild form (16 cases), registered and treated
in Haemophilia Center Timisoara. Mean age of the patients was
23.14 years. We considered two age groups: 16–24 years (60
patients) and 25–34 years (40 patients). Seventeen of the
haemophiliacs were schoolboys, 13-university students, 19-
employees and 51 were handicapped with social support.
RESULTS: Compared with Romanian general population norms
(available only for SF-36 questionnaire) HRQOL is affected in
haemophilia patients in both age groups, although age was not
a strong predictor of HRQOL or utilities. Haemophilia severity
was found to have a strong inﬂuence on HRQOL and utilities.
Regarding the socio-professional status, handicapped with social
support had the lowest HRQOL scores and utilities values.
CONCLUSIONS: Our results conﬁrm the need to develop
special long-term national programs in order to improve
haemophilia treatment, to reduce the number and the severity of
complications, to offer a better social integration of the patients
and to improve their quality of life.
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OBJECTIVES: To establish which characteristics patients con-
sider important in prophylaxis, and if cost of treatment could
inﬂuence their preferences. METHODS: A focus group identi-
ﬁed ﬁve characteristics: type of product (plasma-derived vs.
recombinant), infusions frequency, hemorrhages frequency, pos-
sibility to do vigorous physical activities, possibility to do usual
activities. Patients gave their opinion rating each characteristic
from zero (not important) to 100 (very important). Scenarios
describing hypothetical treatment modalities were administered
to patients who were asked to chose one for each couple pre-
sented. The characteristic “cost”, expressed as increase in health
care taxes, was then added in each scenario and patients were
invited to make again their choices. RESULTS: Fifteen people,
13 adult patients and 2 parents, were enrolled. The characteris-
tic considered most important was “usual activities” (median =
95), followed by “hemorrhages frequency” (86), “infusions fre-
quency” (81), “type of product” (76), “vigorous physical activ-
ities” (69) and ﬁnally “cost” (50). Almost all patients did not
suggest other important characteristics. Eleven patients (73%)
changed at least one choice when “cost” was present. CON-
CLUSIONS: This pilot study allowed us to identify aspects con-
sidered by hemophilia patients as important in prophylaxis.
These results will help us to design a Conjoint Analysis aimed at
evaluating utilities and monetary value of these aspects.
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OBJECTIVES: We evaluated Health-Related Quality of Life
(HR-QoL) in hemophilia people with inhibitors and investigated
if QoL is associated to patients’ clinical status. METHODS: The
COCIS (Cost Of Care of Inhibitors) study was a longitudinal
study involving 52 hemophiliacs (median age 35, 15–64) with
inhibitors, 98% high responders, sequentially enrolled at 11
Italian Hemophilia Care Centers. Information on demographics,
clinical status, health-care resources consumption was prospec-
tively collected. QoL was investigated by means of the generic
instruments EQ-5D and SF-36. RESULTS: With the EQ-proﬁle
the majority of patients reported some/moderate problems 
in domains “pain/discomfort” (72%), “mobility” (66%) and
“usual activities” (54%). Around one third declared some/mod-
erate problems with “anxiety/depression” (34%) and “self-care”
(32%). No more than 6% of patients reported severe problems
in any of the domains. The EQ-Visual Analogue Scale (VAS),
measuring the global health state perception, was normally dis-
tributed, with a median value of 66 (30–95). The SF-Mental
Component Summary (MCS) had a median value of 52.8
(15.5–68.1), while the SF-Physical Component Summary (PCS)
had a median value of 35.2 (15.2–55.0). A strong association
was found between orthopedic status and global HR-QoL (EQ-
VAS, Pearson’s r = 0.56, p < 0.01). In particular, the physical
component of HR-QoL was the most inﬂuenced by the patients’
orthopedic status (Physical Component Summary, Pearson’s r =
-0.359, p < 0.01). Other clinical parameters, in particular
inhibitor titers and bleeding frequency, were not associated with
patients’ HR-QoL. CONCLUSIONS: Modern health care strate-
gies aimed at treating or, better, at preventing hemophilic
arthropathy should be considered to improve quality of life in
inhibitor patients.
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OBJECTIVES: The aim of this work is to evaluate inﬂuence of
clinical and socio-demographic characteristics on the strength of
preferences towards each characteristic. METHODS: We ana-
lyzed data originated by CONAN database from 178 patients.
Patients were asked to make choices between variables of
replacement therapy such as perceived viral safety, risk of
inhibitor development, infusion frequency on prophylaxis, phar-
maceutical dosage form, way of distribution and price.
RESULTS: The value of each characteristic was indicated by its
monetary value: the monetary value for perceived viral safety
was greater for moderate (2547€) compared to severe hemo-
